Skip to main content
OpenTrials
Completed

NCT Number: NCT03162068

Cushing's Osteoporosis Specificities

Osteoporosis induced by glucocorticoids excess constitutes the main cause of secondary osteoporosis. Most of data available are provided from cohort studies of patients treated by corticosteroids, affecting among 1% of population. In contrast, very few data on osteoporosis are available in the Cushing syndrome (CS), a rare disease affecting 1 or 2 million of inhabitants, and characterized by an endogen glucocorticoid excess production. This affection is responsable of frequent fractures, occuring in 30-60% of patients (vertebral asymptomatic in 50% of case, hip, ribs). Fractures occurs often frequently above the threshold usually used for osteoporosis (T-score<-2.5), most often in the range of osteopenia. These data suggest that surface bone density isn't sufficient to characterize bone fragility, architectural factors are probably involved, and should be evaluated. The specificity of osteoporosis induced by endogen glucocorticoids excess in comparison with osteoporosis induced by estrogenic deficiency in post-menopausal women is poorly known, especially in endogen glucocorticoid excess.

A recent microarchitecture studies showed alterations of cortical compartment in patients with Cushing's syndrome, confirming by our preliminary preclinical data from a transgenic murin model of Cushing's syndrome.

In these ten last years, new radiologic tools have been developped, and are able to evaluate bone architecture. The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment.

Therefore, we aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoporosis in Cushing's Syndrome Adrenal Gland Diseases Adrenocortical Hyperfunction Bone Diseases Bone Diseases, Metabolic Cushing Syndrome Endocrine System Diseases Metabolic Diseases Musculoskeletal Diseases Nutritional and Metabolic Diseases Osteoporosis Osteoporosis in Post-menopausal Women

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Clermont-Ferrand

Clermont-Ferrand, Auvergne, 63003, France

About this study

This study are divided in two parts :

  • Cross sectional cohort with both comparison between : Cushing syndrome versus control and cushing syndrome versus post-menopausal women

Outcomes :

Primary outcomes : Analysis thanks to pQCT will be carried out in order to compare radius and tibia bone mineral volume (total, trabecular and cortical)

Secondary outcomes :

Strength parameters, muscle area adipose tissue surface will be assessed. Analysis of body composition thanks to DXA (Dual Energy X ray Absorptiometry), and surface bone mineral density.

Evaluation of Vertebral Fracture Assesment

  • Prospective cohort with a longitudinal follow up on 5 years to assess the evolution of osteoporosis after treatment of Cushing syndrome (surgery or medical treatment).

CS patients are recruited during hospitalisation in endocrinology service Post-menopausal women are recruited within rheumatology service. Cases are recruited thanks to advertisement within CHU.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Cases
  • Healthy Volunteers
  • Men and women> 18 years
  • No known chronic treatment or pathology
  • Absence of tobacco or alcohol
  • Normal bone mineral density for age (Z-score> -2 and T-score> -2.5) and markers of bone remodeling in normal values for age and menopausal status (osteocalcin, CTX)
  • Free 24-hour urinary cortisol (CLU / 24 h) normal Cushing matching by menopausal status, age group, BMI, sex
  • Postmenopausal women
  • Menopause confirmed by hormonal assays
  • Amenorrhea for more than one year
  • Free 24-hour urinary cortisol (CLU / 24 h) normal
  • Osteoporosis confirmed at DXA (T score ≤ -2.5 DS) Post menopausal women matching according to BMI, T-DXA score (T score ≤ -2.5 DS)
  • Cushing's syndrome
  • Endogenous hypercorticism, whatever the cause (dependent or independent ACTH)
  • Active or controlled for less than 5 years

Exclusion criteria

  • Diseases with bone resonance:
  • Disease that can affect phosphocalcium metabolism or promote bone loss: endocrine diseases (hyperparathyroidism, hyperthyroidism); Osteomalacia, malabsorptive intestinal or inflammatory or chronic liver diseases, chronic inflammatory rheumatism.
  • Heavy comorbidities: heart failure or chronic respiratory insufficiency, known severe renal insufficiency.
  • Treatments:
  • Anti-osteoporotic treatments (bisphosphonates, raloxifene, denosumab)
  • Teriparatide; Lithium, thiazide diuretic, treatment with levothyrox suppressive dose, hormone replacement therapy of menopause, anticonvulsants, corticotherapy in progress or in the previous 5 years, anti-aromatases, anti-androgenic
  • Other:
  • Minors, pregnant women
  • Patients unable to express their will (sub-tutelage, curators, dementia).
  • Lack of social security
  • Lack of follow-up
  • Excessive consumption of alcohol

Treatment and study plan

Osteodensitometry and pQCT

Other

The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment. We aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.

Primary outcomes

  1. Comparison of volumetric bone mineral density

    Time frame: at day 1

    thanks to pQCT with evaluation of total, trabecular and cortical compartment, between patients affecting by cushing'syndrome and post-menopausal women

Secondary outcomes

  1. Assessment of strength bone of radius and tibia of the non-dominant limb

    Time frame: at day 1

    comparison Cushing syndrome versus both menopause women and controls : pQCT analysis

  2. Assessment of trabecular and cortical compartment

    Time frame: at day 1

    comparison Cushing syndrome versus both menopause women and controls : pQCT analysis

  3. Comparison of muscle area and surface, adipose tissue

    Time frame: at day 1

    comparison Cushing syndrome versus both menopause women and controls : pQCT analysis

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Collaborators

  • Unité de recherche GReD CNRS UMR6293 / Inserm

Registry information

Official study title

Specificities of Cushing's Osteoporosis Compare to Postmenopausal Osteoporosis : pQCT Analysis in Comparison With a Group of Controls.

Acronym: SOCS

Important dates

Study start
2017
Primary completion
2025
Study completion
2025
First posted
May 22, 2017
Registry last updated
Apr 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.